AML News

Here you will find articles that discuss the latest advances in AML. You will be kept up to date on the newest FDA drug approvals for AML drugs and treatment combinations. You will also learn about newly published research studies and any advances or findings that may contribute to your AML treatment. We will discuss topics such as newly discovered AML genetic mutations, exciting advances on new therapies like CAR-T therapy and NK cells, and improvements in alloegenic stem cell transplant.

Articles posted here will also aim to help answer common questions like "how is AML treated?", "how is AML diagnosed?", and "what causes AML?".

With new AML research being published almost every day, there is a lot to keep track of. The articles in this category will help you stay informed of new AML treatment options and AML research findings which will ultimately make you an empowered patient. Being empowered allows you to take important information to your healthcare team for discussion that will further enhance and personalize your care.

New Drug Combo FDA Approved: Tibsovo (Ivosidenib) and Azacitidine

AML News—May 31, 2022

Servier Pharmaceuticals anncounces that a new treatment combination utilizing their drug Tibsovo (ivosidenib) was FDA approved this past week.

Understanding The IDH1 And IDH2 Mutations

AML News—April 12, 2022

The gene mutations of IDH1 and IDH2 are prevalent in AML. Researchers are learning more about the unique types of IDH mutations and how this information can be used in determining prognosis and which treatments will work best.

Active for AML: 30 Day Activity Challenge During the Month of April

AML News—March 14, 2022

Let’s get Active for AML! Join us during April as we recognize AML Awareness throughout the month by participanting in a 30 day activity challenge managed through our new HealthTree Moves app. Our goal is to start or continue a healthy habit, while building community and bringing awareness to AML.

Progress on OmnImmune, an Allogeneic CAR-T Cell Therapy for AML

AML News—March 14, 2022

OmnImmune, an allogeneic CAR-T cell product shows encouraging results in a small group of people with relapsed/refractory AML. There were many complete and near complete responses seen with OmnImmune starting at lowest dose level in the Phase 1b/2a study. There were no related serious adverse events, including no Graft v Host Disease, neurotoxicity or cytokine release syndrome at any dose level.

Medicare Will Now Cover Free At-Home COVID-19 Tests for Beneficiaries

AML News—February 17, 2022

Diahanna Valentine, financial coach for HealthTree, annouces that Medicare will now cover free at home COVID-19 tests for beneficiaries. She explains how to order these tests and discusses how the weather is an unexpected complication that could interrupt the viability of the shipped COVID tests.

The Shift of the Standard of Care in AML

AML News—February 14, 2022

The standard of care for treating acute myeloid leukemia is shifting as researchers and doctors become more familiar with the way AML behaves in different groups of people. This understanding has lead to the development and approval of many targeted therapies. Arturo Hurtado, a healthcare professional from HealthTree's Patient Experience Team explains the progress and what to expect in the near future.

Finding Free COVID Test For Medicare Beneficiaries

AML News—February 9, 2022

The Biden Administration's new mandate that insurers cover the cost of at-home test does not include beneficiaries of Medicare. Financial advisor, Diahanna Valentine, shares 7 options for Medicare beneficiaries to get access to free COVID tests.

January is National Blood Donor Month

AML News—January 14, 2022

This January is a time of critical blood shortage. Let's raise awareness about the crucial role blood donations play in saving and lengthening the lives of those with acute myeloid leukemia. Share this article with friends and family to encourage them to donate blood!

ASH 2021: Dr. Eunice Wang on Searching for the Most Effective Treatment for Newly Diagnosed FLT3 Positive AML

AML News—January 5, 2022

Dr. Eunice Wang, an AML specialist from Roswell Park Comprehensive Cancer Center in New York discusses the interim results of the phase 3 LACEWING trial looking at the use of gilteritinib + azacitidine vs azacitidine alone in newly diagnosed FLT3 positive AML patients.

Introducing Side Effect Solutions, A Patient-Centric Tool to Find Relief and Help Others

AML News—January 3, 2022

New year, new tool from HealthTree! Introducing Side Effect Solutions, a place where you as a patient can contribute your solution. You can add your solutions for each side effect you experience to contribute to important data collection and patient-centric learning. This tool arms patients with the information they need to discuss their individual situation and health with their doctor.